SG11202007498YA - Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants - Google Patents
Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplantsInfo
- Publication number
- SG11202007498YA SG11202007498YA SG11202007498YA SG11202007498YA SG11202007498YA SG 11202007498Y A SG11202007498Y A SG 11202007498YA SG 11202007498Y A SG11202007498Y A SG 11202007498YA SG 11202007498Y A SG11202007498Y A SG 11202007498YA SG 11202007498Y A SG11202007498Y A SG 11202007498YA
- Authority
- SG
- Singapore
- Prior art keywords
- solid organ
- organ transplants
- tissue transplantation
- specific tolerance
- thymus tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/065—Thymocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/78—Cellulose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Dentistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634377P | 2018-02-23 | 2018-02-23 | |
| PCT/US2019/019137 WO2019165197A1 (en) | 2018-02-23 | 2019-02-22 | Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007498YA true SG11202007498YA (en) | 2020-09-29 |
Family
ID=67687403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007498YA SG11202007498YA (en) | 2018-02-23 | 2019-02-22 | Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12064452B2 (https=) |
| EP (2) | EP3755346B1 (https=) |
| JP (2) | JP7499178B2 (https=) |
| KR (2) | KR102805282B1 (https=) |
| CN (1) | CN112074277A (https=) |
| AU (1) | AU2019225151B2 (https=) |
| BR (1) | BR112020016614A2 (https=) |
| CA (1) | CA3089593A1 (https=) |
| IL (1) | IL276706A (https=) |
| MX (1) | MX2020008590A (https=) |
| SG (1) | SG11202007498YA (https=) |
| WO (1) | WO2019165197A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021034650A1 (en) | 2019-08-19 | 2021-02-25 | Duke University & Medical Center | Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use |
| CN115287262B (zh) * | 2022-01-28 | 2024-04-02 | 浙江中医药大学 | 一种胸腺类器官微球及其制备方法与应用 |
| WO2024042488A1 (en) | 2022-08-24 | 2024-02-29 | Enzyvant Therapeutics Gmbh | Thymic exosome assays, and methods of producing t cell depleted thymus tissue and uses thereof |
| WO2025068989A1 (en) | 2023-09-29 | 2025-04-03 | Enzyvant Therapeutics Gmbh | Device for cultivating and transporting biological tissue |
| JP7627920B1 (ja) | 2023-12-11 | 2025-02-07 | 浩 宮内 | 移植材料の評価方法 |
| CN118203653A (zh) * | 2024-02-06 | 2024-06-18 | 同济大学 | 一种利用胸腺疫苗降低或消除同种异体移植排斥的方法 |
| WO2025226936A1 (en) * | 2024-04-24 | 2025-10-30 | Revivicor, Inc. | Donor-specific tolerance-inducing regimens for xenotransplantation |
| WO2025240817A1 (en) * | 2024-05-17 | 2025-11-20 | The Trustees Of Columbia University In The City Of New York | Thymoliver and methods of constructing thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| EP0667792A1 (en) | 1991-11-22 | 1995-08-23 | The General Hospital Corporation | Specific tolerance in transplantation |
| ATE215375T1 (de) | 1992-01-08 | 2002-04-15 | Gen Hospital Corp | Induzierte toleranz gegen transplantate |
| US5658564A (en) | 1992-02-19 | 1997-08-19 | The General Hospital Corporation | Xenograft thymus |
| US6911220B1 (en) * | 1992-02-19 | 2005-06-28 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
| US5876708A (en) | 1992-02-19 | 1999-03-02 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
| US5766944A (en) * | 1996-12-31 | 1998-06-16 | Ruiz; Margaret Eileen | T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments |
| AUPP977899A0 (en) | 1999-04-15 | 1999-05-13 | Monash University | Improvement of t cell mediated immunity |
| US20040096971A1 (en) * | 2000-12-22 | 2004-05-20 | Blackburn Catherine Clare | Thymic epithelial progenitor cells and uses thereof |
| US20040086508A1 (en) * | 2001-06-05 | 2004-05-06 | Advanced Biotherapy, Inc. | Treatment of organ transplant rejection |
| US7037900B2 (en) | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| US7402432B2 (en) * | 2003-12-12 | 2008-07-22 | The Brigham And Women's Hospital, Inc. | Process for producing T lymphocytes |
| CA2580271A1 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
| WO2006107601A2 (en) * | 2005-04-06 | 2006-10-12 | Duke University | Parathyroid and thymus transplantation in digeorge syndrome subjects |
| EP1993573A2 (en) * | 2006-01-13 | 2008-11-26 | Renovar, Inc. | Systems and methods for monitoring immune responses and predicting outcomes in transplant recipients |
| US20080131441A1 (en) | 2006-09-26 | 2008-06-05 | Manikkam Suthanthiran | Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection |
| US9176122B2 (en) | 2008-03-24 | 2015-11-03 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
| JP2013511554A (ja) | 2009-11-23 | 2013-04-04 | パラティン テクノロジーズ,インコーポレイテッド | メラノコルチン−1受容体特異的線状ペプチド |
| JP2014503217A (ja) * | 2010-12-31 | 2014-02-13 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | マウスにおける自己t細胞の生成 |
| US8637038B2 (en) * | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| WO2015056103A2 (en) * | 2013-10-15 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | High resolution allele identification |
| US12090142B2 (en) | 2018-02-22 | 2024-09-17 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of cancer |
| WO2020010067A1 (en) | 2018-07-06 | 2020-01-09 | Enzyvant Therapeutics, Inc. | Tissue potency determination through quantitative histomorphology analysis |
-
2019
- 2019-02-22 EP EP19757113.6A patent/EP3755346B1/en active Active
- 2019-02-22 AU AU2019225151A patent/AU2019225151B2/en active Active
- 2019-02-22 SG SG11202007498YA patent/SG11202007498YA/en unknown
- 2019-02-22 KR KR1020207023608A patent/KR102805282B1/ko active Active
- 2019-02-22 WO PCT/US2019/019137 patent/WO2019165197A1/en not_active Ceased
- 2019-02-22 CA CA3089593A patent/CA3089593A1/en active Pending
- 2019-02-22 BR BR112020016614-6A patent/BR112020016614A2/pt unknown
- 2019-02-22 KR KR1020257014739A patent/KR20250071282A/ko active Pending
- 2019-02-22 JP JP2020543913A patent/JP7499178B2/ja active Active
- 2019-02-22 MX MX2020008590A patent/MX2020008590A/es unknown
- 2019-02-22 CN CN201980013250.XA patent/CN112074277A/zh active Pending
- 2019-02-22 EP EP24216970.4A patent/EP4545145A3/en active Pending
-
2020
- 2020-08-13 IL IL276706A patent/IL276706A/en unknown
-
2021
- 2021-09-27 US US17/486,045 patent/US12064452B2/en active Active
-
2024
- 2024-01-17 JP JP2024005418A patent/JP2024041955A/ja active Pending
- 2024-07-08 US US18/766,244 patent/US20250114402A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089593A1 (en) | 2019-08-29 |
| AU2019225151B2 (en) | 2026-02-05 |
| AU2019225151A1 (en) | 2020-08-20 |
| JP2024041955A (ja) | 2024-03-27 |
| US20220079989A1 (en) | 2022-03-17 |
| BR112020016614A2 (pt) | 2020-12-22 |
| KR102805282B1 (ko) | 2025-05-13 |
| MX2020008590A (es) | 2020-09-21 |
| EP4545145A2 (en) | 2025-04-30 |
| WO2019165197A1 (en) | 2019-08-29 |
| US12064452B2 (en) | 2024-08-20 |
| CN112074277A (zh) | 2020-12-11 |
| JP2021516224A (ja) | 2021-07-01 |
| EP4545145A3 (en) | 2025-07-02 |
| JP7499178B2 (ja) | 2024-06-13 |
| EP3755346B1 (en) | 2024-12-04 |
| US20250114402A1 (en) | 2025-04-10 |
| KR20210005543A (ko) | 2021-01-14 |
| KR20250071282A (ko) | 2025-05-21 |
| EP3755346A1 (en) | 2020-12-30 |
| EP3755346A4 (en) | 2022-03-09 |
| RU2020124312A (ru) | 2022-03-23 |
| IL276706A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276706A (en) | Transplantation of cultured thymus tissue promoting donor-specific resistance to allogeneic solid organ transplants | |
| EP4620521A3 (en) | Methods and compositions relating to chondrisomes from cultured cells | |
| EP3824074A4 (en) | Cells differentiated from immunoengineered pluripotent cells | |
| AU2019264610A1 (en) | Genetically modified animals and methods for making the same | |
| JO3593B1 (ar) | مركبات تعمل على زيادة الخلايا الجذعية المكونة للدم | |
| UY39292A (es) | VARIANTES DE Fc SILENCIOSAS DE LOS ANTICUERPOS ANTI-CD40 | |
| IL285631A (en) | Methods for producing autologous t cells useful to treat cancers and compositions thereof | |
| GB2526228B (en) | Combined organ and hematopoietic cells for transplantation tolerance of grafts | |
| WO2012012737A3 (en) | Stable tregs and related materials and methods | |
| CL2012002882A1 (es) | Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero. | |
| EP3877415A4 (en) | PROCEDURE FOR ALLOGENE TRANSPLANTATION OF HEMATOPOETIC STEM CELLS | |
| AU2018253575A1 (en) | Natural killer cells from placenta | |
| PL3697459T3 (pl) | Autologiczny substytut przeszczepu kości | |
| WO2017136731A8 (en) | Rapaglutins, novel inhibitors of glut and use thereof | |
| EP3852773A4 (en) | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof | |
| SG11202101297UA (en) | Method for culturing cancer tissue or tissue analogous to cancer tissue | |
| WO2012102937A3 (en) | Benz imidazole compounds that expand hematopoietic stem cells | |
| MX373950B (es) | USO DE UN INHIBIDOR TEMPORAL DE UN GEN p53 PARA LA PROFILAXIS DE LESIÓN POR ISQUEMIA-REPERFUSIÓN. | |
| HK40125806A (en) | Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants | |
| EP4107188A4 (en) | COMPOSITIONS AND METHODS OF ALLOGENIC TRANSPLANTATION | |
| IL289680A (en) | Preparations and methods for tissue preservation for transplantation | |
| WO2017168390A3 (en) | Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells | |
| IL290284A (en) | Autologous thymic tissue transplantation | |
| PL3752598T3 (pl) | Kompozycja allogeniczna | |
| HK40050220A (en) | Methods for allogeneic hematopoietic stem cell transplantation |